Results 81 to 90 of about 87,203 (259)

Flowchart of the participants with overactive bladder syndrome.

open access: yes, 2016
Flowchart of the participants with overactive bladder syndrome.
Hann-Chorng Kuo (307485)   +2 more
core   +1 more source

CRISPR and Gene Augmentation Rescue Trabecular Meshwork Dysfunction in iPSC Models of Lowe Syndrome

open access: yesAdvanced Science, EarlyView.
By modeling Lowe syndrome using patient‐derived iPSCs, this study establishes a human disease model that faithfully recapitulates OCRL deficiency‐associated ciliary and cytoskeletal defects. The model enables evaluation of both mutation‐agnostic DNA augmentation and CRISPR‐mediated mutation correction strategies, both of which restore OCRL function and
Siyu Chen   +11 more
wiley   +1 more source

Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency

open access: yes, 2013
Raymond T Lee,1 Mitchell Bamberger,2 Pamela Ellsworth31University of Massachusetts Medical School, 2UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, 3Division of Urology/Surgery, Warren Alpert Medical School of ...
Ellsworth P, Lee RT, Bamberger M
core  

Lower urinary tract symptoms: Overactive bladder syndrome

open access: yes, 2018
Linda Nazarko explains why nurses are best placed to help women who suffer from an overactive bladder
Linda Nazarko
core   +1 more source

Sacral neuromodulation therapy for urinary and defecatory disorders: experience in a Latin American public hospital

open access: yesRevista Brasileira de Ginecologia e Obstetrícia
Objective: To show the experience of a Latin American public hospital, with SNM in the management of either OAB, NOUR or FI, reporting feasibility, short to medium-term success rates, and complications.
Marcelo Mass-Lindenbaum   +14 more
doaj   +1 more source

Targeting the YAP‐BST2 Axis Overcomes Intrinsic Anti‐PD‐1 Resistance in Metastatic Gastric Cancer

open access: yesAdvanced Science, EarlyView.
Concurrent YAP hyperactivation and Tp53 loss in Atp4b‐expressed parietal cell lineage drives gastric cancer initiation, multi‐organ metastasis, and intrinsic resistance to anti‐PD‐1 therapy. BST2 emerges as a direct YAP‐TEAD transcriptional target that engages PIRA2 on myeloid cells to establish an immunosuppressive microenvironment.
Weihong Zhang   +17 more
wiley   +1 more source

Overactive bladder, differential diagnosis, and clinical utility of fesoterodine

open access: yes, 2012
Jean-Jacques WyndaeleDepartment of Urology, Antwerp University, Antwerp, BelgiumAbstract: Overactive bladder is a symptom syndrome with urgency, frequency and, in many cases, nocturia. Urge incontinence is not present in all.
Wyndaele J-J
core  

What is the prevalence of overactive bladder symptoms in a lower socioeconomic female population? A suggestion for a study in India

open access: yesIndian Journal of Urology, 2007
Although it is suggested that in the United States overactive bladder affects one out of six individuals, this estimation may represent a subset of the population.
Kaytan V Amrute   +2 more
doaj   +1 more source

CHD8‐Dependent Chromatin Licensing Sustains Trophoblast Stem Cell Transcriptional Programs

open access: yesAdvanced Science, EarlyView.
In this study, Huang et al., identify chromatin remodeler CHD8 as an essential factor in TSC maintenance and placental development. CHD8‐dependent chromatin accessibility supports the occupancy of key trophoblast TFs and is coupled to KMT2A‐associated H3K4me3 deposition at TSC stem and cell cycle genes, providing a permissive chromatin environment for ...
Yuanyuan Huang   +16 more
wiley   +1 more source

Evaluation and management of overactive bladder: strategies for optimizing care

open access: yes, 2016
Marcella G Willis-Gray, Alexis A Dieter, Elizabeth J Geller Division of Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA Abstract ...
Willis-Gray MG, Dieter AA, Geller EJ
core  

Home - About - Disclaimer - Privacy